GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lisata Therapeutics Inc (LTS:0HS8) » Definitions » Research & Development

Lisata Therapeutics (LTS:0HS8) Research & Development : $11.33 Mil (TTM As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Lisata Therapeutics Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Lisata Therapeutics's Research & Development for the three months ended in Dec. 2024 was $2.95 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was $11.33 Mil.

Lisata Therapeutics Research & Development Historical Data

The historical data trend for Lisata Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lisata Therapeutics Research & Development Chart

Lisata Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.25 17.58 43.46 12.73 11.33

Lisata Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.01 3.24 2.60 2.54 2.95

Lisata Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lisata Therapeutics  (LTS:0HS8) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Lisata Therapeutics Research & Development Related Terms

Thank you for viewing the detailed overview of Lisata Therapeutics's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Lisata Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lisata Therapeutics Inc (LTS:0HS8) » Definitions » Research & Development
Comparable Companies
MURA ABVC CVM CDIO ALLK QTTB CRIS NEUP UBX NNVC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
LSTA:USA
Address
110 Allen Road, 2nd Floor, Basking Ridge, NJ, USA, 07920
Website
https://www.lisata.com
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.

Lisata Therapeutics Headlines

No Headlines